{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:34:50Z","timestamp":1787020490530,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sequana Medical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Palliat Care"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant Ascites (MA) is a therapeutic dilemma significantly impairing patients\u2019 quality of life (QoL). The Sequana Medical alfapump System (AP), a subcutaneous, externally rechargeable, implantable device, continually draining ascites via the urinary bladder, has been well established in liver cirrhosis, but not yet in MA. The AP-system was evaluated in cancer patients in reducing the need for large volume paracentesis (LVP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective multicentre evaluation of all eligible patients who received an AP for MA-palliation was performed. AP was evaluated for its ability to reduce LVP and cross-correlated with adverse events (AE), survival and retrospective physician-reported QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventeen patients with median age of 63\u2009years (range: 18\u201381), 70.6% female, across 7 primary tumour types were analysed. Median duration of AP-implantation was 60\u2009min (range: 30\u2013270) and median post-implantation hospital stay: 4\u2009days (range: 2\u201324). Twelve protocol-defined AE occurred in 5 patients (29.4%): 4 kidney failures, 4 pump\/catheter-related blockages, 3 infections\/peritonitis and 1 wound dehiscence. Median ascitic volume (AV) pumped daily was 303.6\u2009ml\/day (range:5.6\u2013989.3) and median total AV drained was 28\u2009L (range: 1\u2013638.6). Median patient post-AP-survival was 111\u2009days (range:10\u2013715) and median pump survival was 89\u2009days (range: 0\u2013715). Median number of paracenteses was 4 (range: 1\u201315) per patient pre-implant versus 1 (range: 0\u20131) post-implant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). 71% of patients were reported to have an improvement of at least one physician reported QoL-parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AP appears to be effective in palliating patients with MA by an acceptable morbidity profile. Its broader implementation in oncology services should be further explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03200106\">NCT03200106<\/jats:ext-link>\n                      ; June 27, 2017.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12904-019-0497-3","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T14:02:54Z","timestamp":1575554574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-9645","authenticated-orcid":false,"given":"Christina","family":"Fotopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekristin","family":"Hausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Jalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Malag\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Capel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Stirnimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"issue":"5","key":"497_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"G Becker","year":"2006","unstructured":"Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589\u201397.","journal-title":"Eur J Cancer"},{"issue":"22","key":"497_CR2","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1001\/archinte.161.22.2733","volume":"161","author":"N Aslam","year":"2001","unstructured":"Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733\u20137.","journal-title":"Arch Intern Med"},{"issue":"1","key":"497_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"497_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/1049909111434044","volume":"29","author":"Y Malayev","year":"2012","unstructured":"Malayev Y, Levene R, Gonzalez F. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Care. 2012;29(7):515\u201321.","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"497_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.gtc.2005.12.006","volume":"35","author":"SM Rosenberg","year":"2006","unstructured":"Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin N Am. 2006;35(1):189\u201399 xi.","journal-title":"Gastroenterol Clin N Am"},{"issue":"6","key":"497_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/bjc.2012.343","volume":"107","author":"V Harding","year":"2012","unstructured":"Harding V, Fenu E, Medani H, Shaboodien R, Ngan S, Li HK, et al. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer. 2012;107(6):925\u201330.","journal-title":"Br J Cancer"},{"issue":"5","key":"497_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF03261864","volume":"10","author":"J White","year":"2012","unstructured":"White J, Carolan-Rees G. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE medical technology guidance. Appl Health Econ Health Policy. 2012;10(5):299\u2013308.","journal-title":"Appl Health Econ Health Policy"},{"issue":"8","key":"497_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1089\/jpm.2013.0427","volume":"17","author":"G Narayanan","year":"2014","unstructured":"Narayanan G, Pezeshkmehr A, Venkat S, Guerrero G, Barbery K. Safety and efficacy of the PleurX catheter for the treatment of malignant ascites. J Palliat Med. 2014;17(8):906\u201312.","journal-title":"J Palliat Med"},{"issue":"8","key":"497_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12032-014-0076-7","volume":"31","author":"J Sehouli","year":"2014","unstructured":"Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, et al. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol. 2014;31(8):76.","journal-title":"Med Oncol"},{"issue":"5","key":"497_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jhep.2012.12.020","volume":"58","author":"P Bellot","year":"2013","unstructured":"Bellot P, Welker MW, Soriano G, von Schaewen M, Appenrodt B, Wiest R, et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol. 2013;58(5):922\u20137.","journal-title":"J Hepatol"},{"issue":"7","key":"497_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41395-018-0100-1","volume":"113","author":"F Storni","year":"2018","unstructured":"Storni F, Stirnimann G, Banz V, De Gottardi A. Treatment of malignant ascites using an automated pump device. Am J Gastroenterol. 2018;113(7):1060\u20131.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"497_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/apt.14331","volume":"46","author":"G Stirnimann","year":"2017","unstructured":"Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, et al. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther. 2017;46(10):981\u201391.","journal-title":"Aliment Pharmacol Ther"},{"key":"497_CR13","doi-asserted-by":"publisher","unstructured":"Fotopoulou C, Spiers L, Pickford E, Dina R, Blagden S, Habib N. Continuous low-flow ascites drainage and sequential non-invasive tumor-cell sampling through the urinary bladder via the alfa-pump closed system in platinum-resistant ovarian cancer (PROC): First clinical experience in a cancer patient. Int J Gynecol Cancer. 2013;31(15):5562\u20135562. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.5562","DOI":"10.1200\/jco.2013.31.15_suppl.5562"}],"container-title":["BMC Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-019-0497-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12904-019-0497-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-019-0497-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T19:06:44Z","timestamp":1607022404000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpalliatcare.biomedcentral.com\/articles\/10.1186\/s12904-019-0497-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1186\/s12904-019-0497-3","relation":{},"ISSN":["1472-684X"],"issn-type":[{"value":"1472-684X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"25 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the required institutional research committee of the participating centres. This study was approved by the following ethics committees: North West \u2013 Preston Research Ethics Committee (231306), Ethics Committee at the Medical Faculty of the University of Leipzig (346\/17-ek), Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn Ethics Committee (280\/17), State Medical Association Baden-W\u00fcrttemberg Ethics Committee (B-F-2017-118) and the Cantonal Ethics Committee of Bern (2017\u201301563). This study was undertaken in accordance with the principles of the Declaration of Helsinki of the World Medical Association.All living patients gave their written consent. For patients deceased at study inception, the requirement for informed consent was waived by each centre\u2019s appropriate ethics committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was waived by the ethics committee for deceased patients and consent was obtained for living individuals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors were compensated for the conduct of the study. Prof. Fotopoulou reports grants and personal fees from Sequana Medical to design study and write the paper, during the conduct of the study; advisory board of Roche, Ethicon, Tesaro, Pharmacokinesis, Olympus and Astra Zeneca, outside the submitted work. Prof. Berg reports grants and personal fees from Sequana Medical. Dr. Hausen reports speaker fees from Sequana Medical. Prof. Jalan received a grant from Thaurus, is a consultant for Takeda, board member for JHEP, a speaker for Grifols, outside the submitted work. Dr. Hennig, Prof. Malago and Prof. De Gottardi report no other conflicts of interest. Mr. Capel is an employee of Sequana Medical. Dr. Stirnimann reports being a consultant and speaker for Sequana Medical.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}